A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:
Back to home » Top Stories » CROI 2009
CROI 2009 16th Conference on Retroviruses and Opportunistic Infections
Montréal, Canada
February 8-11, 2009

Smoking Cessation: Hispanics, Nicotine Patch Users Do Best

February 17, 2009

By Tim Horn

An addiction to cigarette smoking is truly difficult for HIV-positive people to break, according to a study comparing two smoking cessation strategies reported Wednesday, February 11, at the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in Montreal. While no more than 10 percent of individuals participating in either strategy abstained from smoking for six months, study presenters Karen Tashima, MD, of Brown University in Providence, Rhode Island, and her colleagues found much higher success rates among Hispanics compared with other racial or ethnic groups.

According to background information provided by Tashima, about 47 to 70 percent of HIV-positive people in the United States smoke, compared with about 20 percent of the general U.S. population. Compounded by the fact that HIV-positive smokers appear to be at a significantly higher risk for conditions such as cancer, chronic lung problems and cardiovascular disease, many experts are eager to incorporate effective smoking cessation programs into HIV medical care.

Tashima’s group explored the effectiveness of two smoking cessation programs, both in conjunction with eight weeks of nicotine patch therapy. In the standard intervention program, 232 people received two three- to four-minute counseling sessions from their health care providers to discuss quitting and to review smoking cessation literature. In the Positive Paths program—a “motivationally enhanced” strategy—212 people participated in four 30-minute sessions to talk with trained counselors about setting goals, taking responsibility and making positive changes.

About 72 percent of the patients completed six months of the study. Sixty-two percent of the study completers were men, 52 percent were white, 18 percent were black, and 16 percent were Hispanic. On average, the study participants smoked about a pack of cigarettes a day.

Quit rates were based on self-reports of abstinence, confirmed using a lab test to check for the presence of nicotine.

When analyzing results involving all patients enrolled in the study—including those lost to follow-up—Tashima’s group reported that 9 percent of those enrolled in the study were smoke-free after six months. This includes 9 percent of those in the Positive Paths program and 10 percent of those in the standard intervention program. When looking only at those who actually completed all six months of the study, abstinence rates were somewhat higher: 12 percent in the Positive Paths program and 14 percent in the standard intervention program.

Interestingly, higher quit rates were seen among Hispanics: 19 percent overall, including 14 percent in the Positive Paths group and 24 percent in the standard intervention group. Quit rates were lowest among blacks: 5 percent overall, including 9 percent in the Positive Paths group and 0 percent in the standard intervention group. The overall difference between Hispanics and blacks was statistically significant, meaning it was too great to have occurred by change.

About one third of the study volunteers opted not to use the nicotine patch—not one of whom remained smoke-free within six months. In fact, using the patch and having a high motivation to quit and remain smoke-free were the strongest predictors of success in either program studied.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       

More from CROI 2009

HIV/AIDS Complications

March 4, 2009
HIV and Women
February 26, 2009
HIV and the Brain: What to Watch Out For
February 25, 2009
HIV and Cancer: Prevalence and Prevention
February 23, 2009
Half of Deaths in People With HIV No Longer From AIDS
February 20, 2009
Testosterone Therapy: Good for Women Too
Lymphoma: Death Rates Still High, but Cancer May Be Predicted
February 19, 2009
Quarter of U.S. Positive Women Not Receiving Annual Pap Smears
February 18, 2009
HDL and Small HDL Particles Predict Cardio Problems in HIV
Scientists Still Seeking Clues to Abacavir Heart Attack Mystery
February 17, 2009
Smoking Cessation: Hispanics, Nicotine Patch Users Do Best
Nerve Damage Is a Common Problem in People With HIV
February 11, 2009
PIs, Abacavir and Cardiovascular Disease: What’s the Risk?
D:A:D Study: Reduce Modifiable Risk Factors to Improve Survival
HIV Itself Is a Major Heart Disease Risk Factor
February 10, 2009
Age, Diabetes & a Bigger Waist Line Tied to Cognitive Problems in HIV
February 9, 2009
Diabetes Drug Avandia Helps Reverse Lipoatrophy

HIV Transmission and Prevention

February 27, 2009
Prevention Highlights, Part 1: PrEP
Prevention Highlights, Part 2: Treatment as Prevention
February 13, 2009
Microbicides Make a Comeback
February 9, 2009
HIV Treatment Greatly Reduces, But Doesn’t Eliminate Transmission

Starting and Switching Treatment

February 12, 2009
Isentress Shows Long-Term Benefits in Treatment-Experienced Patients
Antidepressants Improve Viral Load Response to Treatment Due to Better Adherence
February 10, 2009
Start HIV Treatment Early—But When?
February 9, 2009
Kaletra-to-Isentress Switch Helps Lipids, but With Viral Rebound Risk

Experimental HIV Drugs

February 20, 2009
Antiretroviral Highlights from CROI
February 10, 2009
IL-2 Fails in Two Large Studies
February 9, 2009
GS 9350 and SPI-452: Emerging Alternatives to Norvir Boosting


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.